NBI-1065845: Clinical Trials

6 trials of NBI-1065845, newest first
ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 recruiting, 1 completed. 5 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 35Recruiting 5
Phase 21Completed 1

Follow NBI-1065845: new trials by email Literature Review of NBI-1065845 trials Research Report on NBI-1065845

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Osavampator, Placebo - Major Depressive Disorder		Phase 3RecruitingNeurocrine Biosciences5502025-08-182026-10-22
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NBI-1065845, Placebo - Major Depressive Disorder		Phase 3RecruitingNeurocrine Biosciences2002025-05-302026-08-10
Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NBI-1065845 - Major Depressive Disorder		Phase 3RecruitingNeurocrine Biosciences8502025-04-162026-07-24
NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NBI-1065845, Placebo - Major Depressive Disorder		Phase 3RecruitingNeurocrine Biosciences2002025-03-312026-08-11
Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
NBI-1065845, Placebo - Major Depressive Disorder		Phase 3RecruitingNeurocrine Biosciences2002025-01-222025-10-29
Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD)
Placebo, NBI-1065845 - Major Depressive Disorder		Phase 2CompletedNeurocrine Biosciences1832022-02-212025-01-15

Conditions studied

Depressive Disorder, Major (6)  ·  Depression (5)  ·  Mental Disorders (1)

Sponsors

Neurocrine Biosciences (6)

Countries

United States (6)  ·  Bulgaria (4)  ·  Canada (3)  ·  Poland (3)  ·  Slovakia (3)  ·  Belgium (2)  ·  Czechia (2)  ·  Estonia (2)  ·  Finland (2)  ·  Hungary (2)  ·  Italy (2)  ·  Latvia (2)  ·  Lithuania (2)  ·  Romania (2)  ·  Spain (2)

NIH funding

2025 (1)